JPRN-jRCT2080220437未知3 期
An Open-Label, Multi-Center, Long Term Study to Investigate the Safety and Efficacy of Budesonide Turbuhaler Treatment for 48 Weeks (Following 6 Weeks Phase III Study) in Japanese Children With Bronchial Asthma Aged 5 Years to 15 Years Old
适应症
试验速览
- 阶段
- 3 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 5age old 至 <= 15age old（—）
- 性别
- All
入选标准
- •Ages Eligible for Study: 5 Years - 15 Years
- •Genders Eligible for Study: Both
- •Inclusion Criteria:
- •- When the investigator will obtain the signed written informed consent of Phase III study (D5254C00769) from patient's legal representative, the investigator will also provide the information of this study
排除标准
- •- Respiratory infections that, in the opinion of the investigator(s), may affect the efficacy evaluation e.g., lower airways infection such as pneumonia, infection with no available effective antimicrobial drugs or with deep seated mycosis
研究者
相似试验
进行中（未招募）
1 期
An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component - Neptune IIower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).MedDRA version: 9.1 Level: LLT Classification code 10004446 Term: Benign prostatic hyperplasiaEUCTR2008-001212-20-GBAstellas Pharma Europe B.V.800
进行中（未招募）
1 期
A long-term study to examine the safety and efficacy of a combination of solifenacin succinate and tamsulosin hydrochloride to treat male patients with lower urinary tract symptoms associated with prostate gland enlargement with a substantial storage component (such as increased urinary frequency, urgency and need to get up in the night to urinate).ower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).MedDRA version: 14.0Level: PTClassification code 10004446Term: Benign prostatic hyperplasiaSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2008-001212-20-NLAstellas Pharma Europe B.V.1,067
进行中（未招募）
不适用
An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component - Neptune IIower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).MedDRA version: 12.0Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2008-001212-20-CZAstellas Pharma Europe B.V.1,100
进行中（未招募）
1 期
An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component - Neptune IIower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2008-001212-20-FRAstellas Pharma Europe B.V.800
进行中（未招募）
不适用
An open-label, long term multi-center study to assess the safety and efficacy of fixed dose combinations of solifenacin succinate (6 mg and 9 mg) with tamsulosin hydrochloride OCAS 0.4 mg, in male subjects with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) with a substantial storage component - Neptune IIEUCTR2008-001212-20-HUAstellas Pharma Europe B.V.800